Rusan Healthcare Pvt. Ltd. has launched APOSAN® 3ml Pen, a multi-dose delivery device for apomorphine hydrochloride injection, aimed at helping patients with Parkinson’s disease manage motor fluctuations, commonly known as “ON-OFF” episodes. The launch expands the company’s Parkinson’s portfolio and adds a portable rescue-therapy option for patients who need rapid symptom control.
The new device delivers apomorphine hydrochloride solution for injection in 10 mg/ml, 3 ml pre-filled cartridges, through a dial-a-dose pen mechanism. Rusan said the pen has an enhanced dose-visibility window, designed to support accurate administration, reduce handling complexity and lower the risk of dosing errors. The lightweight, portable format is meant to allow patients to self-administer subcutaneous treatment at home with greater convenience.
Rusan said the APOSAN® 3ml Pen completes its apomorphine range in India, which now includes 2 ml injections, 3 ml pre-filled cartridges with a multi-dose pen device and 5 ml formulations for continuous infusion pumps. The company said these options are intended to address different clinical needs in Parkinson’s management, from rapid rescue from OFF episodes to sustained symptom control through infusion-based therapy.
The company first introduced APOSAN® in India in 2018 as the first Indian launch of apomorphine hydrochloride solution for injection in 2 ml and 5 ml ampoules. Since then, Rusan said it has seen strong clinical impact and consistently positive patient experiences, reinforcing apomorphine’s role as an important option in the treatment of Parkinson’s disease.
The launch comes as Parkinson’s disease continues to affect a large and growing patient population globally, with India representing a significant share of cases. Rusan said the broader understanding of the disease is also changing, with early-onset Parkinson’s disease emerging as a growing part of the burden. The company cited research showing that incidence and prevalence of early-onset Parkinson’s tripled between 1990 and 2021, highlighting the need for greater awareness, early diagnosis and wider access to care.
Ms Malavika Kaura Saxena, Chief Marketing Officer, Rusan Healthcare, said the APOSAN® 3ml Pen marks “a major step forward,” adding that it offers a portable, multi-use system for reliable apomorphine delivery. She said the accompanying APOSAN® HOPE Program provides “structured onboarding, guided support, and patient-centric services” to help patients and families adopt and sustain the therapy with confidence.
Dr. Kunal Saxena, Managing Director, Rusan Pharma Limited, said the launch reflects the company’s commitment to advancing Parkinson’s care through accessible and scalable treatment solutions. He said Rusan’s fully integrated manufacturing model, including internal API production at its USFDA and EU GMP-accredited facility, helps maintain quality, reduce dependence on external suppliers and secure a consistent supply chain for the product.
With APOSAN® 3ml Pen, Rusan is positioning itself to expand access to advanced Parkinson’s therapy in India while offering patients a more flexible and practical way to manage a chronic neurological condition that affects both older adults and an increasing number of younger patients.
